---
schema_version: "secwatch.filing_event.v1"
accession: "0000915913-26-000032"
form_type: "8-K"
ticker: "ALB"
cik: "0000915913"
company_name: "ALBEMARLE CORP"
filed_at: "2026-03-06T23:59:59+00:00"
generated_at: "2026-05-15T19:14:02.756509+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Albemarle completes sale of controlling Ketjen stake for ~$547M; launches $500M debt tender, redeems $650M notes

## Summary
- Sale to KPS Capital Partners: ~$547M cash ($22M included with Ketjen); combined with Eurecat sale totals ~$670M pre-tax.
- Albemarle retains 49% minority stake in Ketjen; 100% of Performance Catalyst Solutions kept in-house.
- Proceeds to fund debt reduction: cash tender offers up to $500M for 4 series of senior notes (2052, 2044, 2029, 2032).
- Full redemption of $650M 4.650% Senior Notes due 2027 on March 12, 2026, plus accrued interest.
- Tender offers expire March 30, 2026; early tender deadline March 13, 2026, with $50 per $1,000 premium.

## SEC filing metadata
- accession: 0000915913-26-000032
- form_type: 8-K
- ticker: ALB
- cik: 0000915913
- company_name: ALBEMARLE CORP
- filed_at: 2026-03-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.01, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/915913/000091591326000032/0000915913-26-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/915913/000091591326000032/alb-20260302.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000915913-26-000032
- JSON: https://secwatch.observer/filing/0000915913-26-000032.json
- Plain text: https://secwatch.observer/filing/0000915913-26-000032.txt

## Source-grounded claims
- claim_id: baba5a73f9f8be40234ec9ddf4178b5e5c19a9c4
  claim: ALBEMARLE CORP completed a disposition involving ChemCat AcquisitionCo, LLC for approximately $547 million in cash (closed 2026-03-02).
  evidence_excerpt: arrangements), and marketing catalysts and related products on a global basis. In connection with the Sale, Albemarle expects to receive an aggregate amount of approximately $547 million in cash, inclusive of $22 million in cash included with Ketjen at the time of the Sale. Together with the sale of its 50% interest in the Eurecat joint venture to Axens SA,
  evidence_url: https://www.sec.gov/Archives/edgar/data/915913/000091591326000032/0000915913-26-000032-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.